Liraglutide vs Semaglutide (Saxenda vs Wegovy): Head-to-Head Evidence [2026]

Liraglutide and semaglutide are both GLP-1 receptor agonists made by the same company, Novo Nordisk, and both are approved for chronic weight management under the brand names Saxenda (liraglutide 3.0 mg) and Wegovy (semaglutide 2.4 mg). They share a mechanism, but they are not interchangeable, and one head-to-head trial settled the efficacy question fairly clearly. This guide walks through the actual evidence, where it is strong and where it is thin, and how to think about cost, side effects, and which drug fits which person in 2026.

The short version of the science

Both drugs mimic glucagon-like peptide-1 (GLP-1), a hormone your gut releases after you eat. GLP-1 does a few things that matter for weight: it slows how fast your stomach empties, it acts on appetite centers in the brain to make you feel full sooner, and it nudges the pancreas to release insulin when blood sugar is high. Less hunger plus earlier fullness usually means you eat less without white-knuckling it.

The big practical difference is how long each drug lasts in the body. Liraglutide has a half-life of roughly 13 hours, so Saxenda is injected once a day. Semaglutide was re-engineered to bind to a blood protein called albumin, which protects it from being cleared. Its half-life is about a week, so Wegovy is injected once weekly. That longer, steadier exposure is also why semaglutide tends to produce more weight loss, not just more convenience.

There is a deeper reason the daily-versus-weekly split matters. With a daily drug, blood levels rise and fall every 24 hours, and the appetite effect can wax and wane through the day. With a weekly drug, levels stay high and flat once you reach steady state, so the hunger-quieting effect is more constant. Both drugs are also large peptide molecules, which is why neither of these versions can be a pill you swallow at the target weight-loss dose; they have to be injected under the skin with a small needle. (Oral semaglutide exists for diabetes and now for weight, but at different doses and with food-timing rules, and that is a separate product from Wegovy.)

How they compare at a glance

Feature	Liraglutide (Saxenda)	Semaglutide (Wegovy)
Drug class	GLP-1 receptor agonist	GLP-1 receptor agonist
Maker	Novo Nordisk	Novo Nordisk
Dosing	Once daily, subcutaneous	Once weekly, subcutaneous
Target weight-management dose	3.0 mg/day	2.4 mg/week
FDA approval for weight (adults)	December 2014	June 2021
FDA approval for teens 12+	December 2020	December 2022
Average weight loss at ~68 weeks	~6% of body weight	~15% of body weight
Cardiovascular outcome data	LEADER (in diabetes)	SELECT (in obesity, no diabetes)
Generic available (2026)	Yes, generic liraglutide	No
Approx. list price/month	~$1,350	~$1,350

The head-to-head evidence: STEP 8

There is exactly one major randomized trial that pits these two drugs directly against each other for weight loss, and it is the most important piece of evidence in this comparison. The STEP 8 trial, published in JAMA in January 2022, randomized 338 adults with overweight or obesity and without diabetes to once-weekly semaglutide 2.4 mg, once-daily liraglutide 3.0 mg, or placebo, all on top of diet and exercise counseling, for 68 weeks.

The results were not close. Average weight change from baseline was −15.8% with semaglutide versus −6.4% with liraglutide. That is a 9.4 percentage-point gap, and it was statistically significant. Put another way, semaglutide produced roughly two and a half times the proportional weight loss.

The responder data tell the same story. About 70.9% of people on semaglutide lost at least 10% of their body weight, compared with 25.6% on liraglutide. Dropout from side effects and other reasons was also lower on semaglutide (13.5%) than on liraglutide (27.6%) over the trial.

A few honest caveats. STEP 8 was a single trial with 338 people, which is modest, and it was funded by Novo Nordisk, which makes both drugs. It enrolled adults without diabetes, so it does not directly tell you how the two compare in someone with type 2 diabetes. And the daily-injection burden of liraglutide may have contributed to its higher dropout rate, which can drag down average results in a way that is partly about adherence, not just biology. None of that overturns the headline, but it is worth knowing the gap reflects real-world tolerability as well as raw potency.

Outcome at 68 weeks (STEP 8)	Semaglutide 2.4 mg	Liraglutide 3.0 mg
Mean weight change	−15.8%	−6.4%
Lost ≥10% of body weight	70.9%	25.6%
Discontinued treatment	13.5%	27.6%
Injection frequency	Weekly	Daily

What the standalone trials showed

Each drug also has its own pivotal weight-loss trial, which lines up with STEP 8.

For liraglutide, the SCALE Obesity and Prediabetes trial (NEJM, 2015) enrolled 3,731 adults without diabetes. People on liraglutide 3.0 mg lost about 8% of their body weight on average over 56 weeks, versus roughly 2.6% on placebo, a placebo-corrected difference of a little over 5 percentage points. That was a meaningful result for its time and made Saxenda the first GLP-1 approved specifically for obesity.

For semaglutide, the STEP 1 trial (NEJM, 2021) enrolled 1,961 adults without diabetes. People on semaglutide 2.4 mg lost about 14.9% of their body weight over 68 weeks, versus about 2.4% on placebo. STEP 1 is the trial that reset expectations for what a weight-loss drug could do short of surgery.

These two trials used slightly different lengths and populations, so you cannot subtract one number from the other and call it a fair fight. That is exactly why STEP 8 matters: it is the controlled comparison, and it confirms the indirect signal.

It is also worth being honest about what these averages hide. Weight loss with GLP-1 drugs is not uniform. In every one of these trials, some people lost a large amount and some lost almost nothing. The average tells you what to expect across a group, not what will happen to you specifically. A minority of people are "non-responders" who lose less than 5% even at the full dose, and that pattern shows up with both drugs. So while semaglutide wins on the average, an individual who tolerated liraglutide well and lost a meaningful amount on it is not doing anything wrong by staying on it.

Dosing and titration: what the schedule actually looks like

Neither drug is started at its target dose. Both ramp up slowly to let the gut adjust, which is the single biggest factor in how rough or smooth the first couple of months feel.

Liraglutide (Saxenda) starts at 0.6 mg once daily and increases by 0.6 mg each week: 0.6, then 1.2, 1.8, 2.4, and finally 3.0 mg. So it takes about five weeks to reach the full weight-loss dose, assuming you tolerate each step. That is a daily injection the whole time.

Semaglutide (Wegovy) starts at 0.25 mg once weekly and steps up roughly every four weeks: 0.25, then 0.5, 1.0, 1.7, and finally 2.4 mg. So it takes about 16 weeks to reach the full dose. The slower escalation is part of why many people tolerate it. If a dose increase causes too much nausea, prescribers often hold at the current dose longer before going up.

Titration step	Liraglutide (Saxenda)	Semaglutide (Wegovy)
Starting dose	0.6 mg daily	0.25 mg weekly
Escalation interval	Weekly	Every ~4 weeks
Target dose	3.0 mg daily	2.4 mg weekly
Time to target	~5 weeks	~16 weeks
Injections per month at target	~30	~4

The practical takeaway: liraglutide gets you to full dose faster but asks for a shot every day. Semaglutide takes months to reach full strength but then settles into four injections a month. For someone who hates needles or struggles with daily routines, that difference is not trivial. For a related breakdown of how to start safely, see our semaglutide dosing schedule guide.

Beyond weight: cardiovascular and metabolic effects

Weight loss is the headline, but both drugs have outcome data that go further, and the strength of that evidence differs by drug and by population.

Liraglutide's cardiovascular evidence comes from the LEADER trial (NEJM, 2016), which studied liraglutide 1.8 mg (the Victoza dose, used for type 2 diabetes) in 9,340 people with diabetes at high cardiovascular risk. Over a median 3.8 years, liraglutide cut the risk of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) from 14.9% to 13.0%, a roughly 13% relative reduction, and it lowered all-cause death. Important caveat: this was at the diabetes dose, in people with diabetes. It is not direct proof that Saxenda's 3.0 mg dose protects the heart in people using it purely for weight loss.

Semaglutide's cardiovascular evidence is more directly relevant to the weight-loss population. The SELECT trial (NEJM, 2023) enrolled more than 17,600 adults who had established cardiovascular disease and were overweight or obese but did not have diabetes, which is the closest match to a typical Wegovy candidate. Semaglutide 2.4 mg reduced major adverse cardiovascular events by about 20% versus placebo. On the strength of SELECT, the FDA expanded Wegovy's label to include reducing cardiovascular risk in that population, an indication liraglutide does not carry for weight management.

So the grading here is uneven. Semaglutide has stronger, more directly applicable cardiovascular evidence in the obesity-without-diabetes group. Liraglutide has solid cardiovascular evidence too, but at a different dose in a different population.

Side effects and safety

The side-effect profile is similar between the two because they share a mechanism. The common complaints are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach pain, especially when starting or increasing the dose. These tend to fade over weeks. Slow dose escalation is the main tool for keeping them manageable, and our full guide to GLP-1 side effects covers practical steps.

Both carry the same class-wide boxed warning for thyroid C-cell tumors, based on rodent studies. Whether this risk translates to humans is unknown, but because of it, both drugs are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or the genetic syndrome MEN 2. Both also list pancreatitis, gallbladder problems, and kidney issues (often from dehydration after heavy vomiting or diarrhea) as risks to watch.

One difference worth flagging: in STEP 8, more people quit liraglutide than semaglutide. Some of that is the daily-injection burden, and some is tolerability. A daily shot is simply harder to stay consistent with than a weekly one, and adherence is part of the safety and effectiveness picture in the real world.

A few specific safety points are worth spelling out, because they apply to both drugs and because people often miss them:

• Dehydration and kidneys. Most serious kidney problems with these drugs trace back to severe vomiting or diarrhea causing fluid loss. The drugs themselves are not directly toxic to kidneys in most people. The fix is mundane: stay hydrated, and if you cannot keep fluids down, call your prescriber rather than pushing through.
• Gallbladder. Rapid weight loss of any kind raises the risk of gallstones, and both drugs list gallbladder events. New severe upper-right belly pain deserves a call to your doctor.
• Pancreatitis. Both labels warn about it, though large trials have not shown a clear, large increase. Persistent severe abdominal pain that radiates to the back is the warning sign to act on.
• Low blood sugar. On their own, these drugs rarely cause dangerously low blood sugar. The risk rises sharply if you also take insulin or a sulfonylurea, which is mainly a concern for people with diabetes. Doses of those other drugs often need to come down.

The reassuring part is that liraglutide has been on the market since 2010 (for diabetes) and 2014 (for weight), so its long-term safety profile is unusually well characterized for an obesity drug. Semaglutide's record is shorter but now backed by very large trials like SELECT.

Cost, generics, and access in 2026

This is where the comparison gets more interesting than the efficacy data alone might suggest.

Both Saxenda and Wegovy carry list prices around $1,350 per month without insurance, which is out of reach for most people paying cash. Insurance coverage for obesity drugs remains patchy, and prior authorization is common. For a deeper breakdown, see our 2026 GLP-1 cost guide and the running price tracker.

The big 2026 shift is generics. The FDA approved the first generic liraglutide products starting in 2024 (Teva and Hikma), and a generic liraglutide indicated for weight loss has since reached the market. Generic liraglutide can run well below brand Saxenda depending on the pharmacy. Semaglutide has no generic in the United States in 2026, because its patents have not expired, so Wegovy stays brand-only and pricey. That flips part of the calculus: semaglutide wins on potency, but liraglutide may win on out-of-pocket cost for someone without coverage.

Special populations: where the choice changes

The "semaglutide usually wins" rule has exceptions that depend on who you are.

Teens. Both drugs are approved for adolescents 12 and older with obesity. Liraglutide was approved for this group in December 2020 based on a dedicated trial, and Wegovy followed in December 2022 on the strength of the STEP TEENS trial, where semaglutide produced large weight loss in adolescents. For a family weighing a daily shot against a weekly one in a 13-year-old, the weekly option is often easier to sustain.

People with type 2 diabetes. Neither Saxenda nor Wegovy is primarily a diabetes drug, but both molecules have diabetes versions (Victoza for liraglutide, Ozempic for semaglutide). If diabetes is part of the picture, the decision usually folds into a broader conversation that may also include tirzepatide. Weight loss tends to be a bit smaller in people with diabetes than in people without, for both of these drugs.

People who had bad nausea before. Some people are simply more sensitive to GLP-1 side effects. For them, the slower 16-week semaglutide ramp can be gentler than the faster liraglutide ramp, even though the weekly drug is more potent. Others find that a daily drug, which they can pause more granularly, gives them more control. There is no universal answer here.

People with a thyroid or pancreas history. Both drugs are contraindicated in medullary thyroid carcinoma and MEN 2. A personal history of pancreatitis is a reason for caution with either. These are not areas to self-decide; they require a prescriber's judgment.

What happens if you stop

This is the part many people overlook, and it applies almost identically to both drugs. GLP-1 medications manage weight while you take them; they are not a cure that resets your body. When people stop, appetite generally returns and a meaningful portion of lost weight tends to come back over the following year. This was seen clearly in the semaglutide withdrawal data and is consistent with how liraglutide behaves, since they share a mechanism.

The honest framing is that both drugs are best thought of as long-term tools, more like blood-pressure medication than an antibiotic course. That has cost implications, because long-term use means paying for the drug for years, and it is one reason the generic-versus-brand price gap matters so much. If a generic liraglutide is what someone can actually afford to stay on, sustained modest weight loss may beat a brief, dramatic loss on a brand drug they have to abandon when the cost becomes unbearable.

Who each drug is for

For most people whose main goal is the most weight loss, the evidence points to semaglutide. STEP 8 showed it beat liraglutide on every weight endpoint, and SELECT gives it cardiovascular data that maps onto the typical user. The weekly shot is also easier to stick with.

Liraglutide still has a real place. It makes sense when semaglutide is unavailable or unaffordable and a lower-cost generic is the difference between treatment and none. Its decade-plus track record means its long-term safety is well characterized. Some people also tolerate it better, and a small daily dose ramp can be gentler on the stomach for those who are very sensitive. People who need or prefer a daily routine for adherence reasons may do fine on it.

If you have type 2 diabetes, the conversation changes, because semaglutide and tirzepatide both have their own diabetes data. Our comparison of semaglutide vs. tirzepatide is worth a read, since tirzepatide (Zepbound/Mounjaro) outperforms both of these drugs on weight in head-to-head and indirect data. For switching considerations between agents, see our guide to switching GLP-1 medications.

Frequently Asked Questions

Is semaglutide stronger than liraglutide?

Yes, for weight loss. In the head-to-head STEP 8 trial, semaglutide 2.4 mg produced about 15.8% weight loss versus 6.4% for liraglutide 3.0 mg over 68 weeks, roughly two and a half times more. Semaglutide also lasts about a week per dose versus liraglutide's roughly 13 hours, which is why it is dosed weekly and is more potent.

Can I switch from Saxenda to Wegovy?

Many people do, usually for better results or the convenience of a weekly shot. This should be done with a prescriber, who will typically restart dose escalation rather than jumping straight to the target dose, to limit nausea and other gastrointestinal side effects. Do not switch on your own without medical guidance.

Is there a generic version of either drug?

Generic liraglutide became available in the United States starting in 2024, including a version indicated for weight loss, which can cost less than brand Saxenda. There is no generic semaglutide approved in the United States as of 2026, so Wegovy remains brand-only at a high list price.

Do both drugs protect the heart?

Both have cardiovascular outcome data, but they are not equivalent. Semaglutide's SELECT trial showed about a 20% reduction in major cardiovascular events in people with obesity and existing heart disease but no diabetes, the population most like Wegovy users. Liraglutide's LEADER trial showed benefit too, but at the diabetes dose in people with diabetes, so it is less directly applicable to weight-management use.

Which has fewer side effects?

The side-effect types are similar because both are GLP-1 drugs, mainly nausea, vomiting, diarrhea, and constipation. In STEP 8, more people stopped liraglutide than semaglutide (27.6% vs. 13.5%), which reflects both tolerability and the burden of a daily injection. Slow dose escalation helps with either drug.

This article is for general education and is not medical advice. Talk to a licensed clinician before starting, stopping, or switching any GLP-1 medication.

Sources

• Rubino DM, et al. STEP 8 Randomized Clinical Trial (JAMA, 2022) — direct head-to-head of semaglutide 2.4 mg vs. liraglutide 3.0 mg
• Pi-Sunyer X, et al. SCALE Obesity and Prediabetes trial (NEJM, 2015) — liraglutide 3.0 mg pivotal weight-loss trial
• Wilding JPH, et al. STEP 1 trial (NEJM, 2021) — semaglutide 2.4 mg pivotal weight-loss trial
• Marso SP, et al. LEADER trial (NEJM, 2016) — liraglutide cardiovascular outcomes in type 2 diabetes
• Lincoff AM, et al. SELECT trial (NEJM, 2023) — semaglutide cardiovascular outcomes in obesity without diabetes
• FDA: Wegovy approval for patients aged 12 and older — adolescent indication
• FDA: First generic once-daily GLP-1 (liraglutide) injection — generic liraglutide availability
• PubMed search: semaglutide vs liraglutide weight loss — broader literature